|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. researchers not pressuring or paying any third party to obtain oocytes for them, 11, 92, 102, 128 Statutory bans, 16 Stem Cell Bank, in the UK, 44, 77, 92 Stem Cell Oversight Committee, 78 Stem Cell Task Force, 25 derivation of, 16 safe handling and storage of, 4, 90, 101–102, 127 standardization of and validation of results, 4 Stem Cells and the Future of Regenerative Medicine, 19 Stored cells confidence in the value of, 12 disclosure that cells and cell lines may be kept for many years, 90, 102, 127 T Targeting in the development of drugs, 2 in genes, 117 Taxonomies, 49 Testing potential of derived cells to contribute usefully when implanted, 44 therapeutic drugs, 45 Therapeutic potentials, 50, 76 involving cloning, 19 Timing of consent to donate excess blastocysts, 88 obtaining from each donor at time of donation, 88, 101, 127 Tissue rejection, overcoming, 34 Tracking, 72 Transparency, 51 Transplantation uses, 34, 42, 44–45, 67, 72–73, 105, 120 Type I diabetes, 33 U U.N. General Assembly, 74n, 76 Undifferentiated cells, 32, 120 United Kingdom, 77 national body established in, 59 procurement practices in, 66 United States Code (USC), 72 University of Wisconsin, 15 U.S. state law on hES cell research, 74–76 USC. See United States Code V Varmus, Harold, 23 Viral infections, 33 Voluntary donations, ensuring to all donors, 84–85 W Web-based primer, 56 Women possible exploitation of, 48 undergoing hormonal induction to generate oocytes, 87, 101, 127 X Xenograft or xenotransplant, 39, 73, 120 Z
|
|
|||||||||||||||
